Skip to Content

Join the 'Non-Small Cell Lung Cancer' group to help and get support from people like you.

Non-Small Cell Lung Cancer News

Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 6 days ago by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Lupron, Accutane, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Femara, Tretinoin, Gleevec, Fluorouracil, Rituxan, Colorectal Cancer, Zoladex, Lung Cancer

FDA Approves Iressa (gefitinib) for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

Posted 12 days ago by Drugs.com

July 13, 2015 – The U.S. Food and Drug Administration today approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Lung cancer is the leading cause of cancer-related death among men and women in the U.S. and, though more common in men, the number of deaths from lung cancer in women is increasing. According to the National Cancer Institute, an estimated 221,200 Americans will be diagnosed with lung cancer, and 158,040 will die from the disease this year. NSCLC is the most common type of lung cancer. Mutations in the EGFR gene are present in about 10 percent of NSCLC tumors. Iressa is a kinase inhibitor that blocks proteins that promote the development of cancerous cells with certain EGFR ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Iressa, Gefitinib

Smoking Blamed for Half of Deaths From Major Cancers in People Over 35

Posted 15 Jun 2015 by Drugs.com

MONDAY, June 15, 2015 – About half of U.S. deaths caused by certain cancers – including lung, colon and pancreatic tumors – can be attributed to smoking, a new American Cancer Society study estimates. In 2011, nearly half of the almost 346,000 deaths from 12 cancers in people 35 and older were linked to smoking, the study found. "Despite large declines in smoking in the United States over the last 50 years, smoking still accounts for the majority of lung cancer deaths," said study co-author Rebecca Siegel, the American Cancer Society's director of surveillance information. The researchers looked at 12 cancers known to be caused by smoking. In 2011, they found that 346,000 people died from these types of cancer. The researchers also had data on current and former smoking, and found that almost 168,000 of these deaths were due to tobacco. For some cancers, the researchers said smoking ... Read more

Related support groups: Cancer, Smoking, Smoking Cessation, Nicotine, Colorectal Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Nicorette, Nicoderm CQ, Nicotrol Inhaler, Commit, Habitrol, Nicotrol NS, Nicorelief, Nicorette DS, ProStep, Nicotrol TD

Surgery May Boost Survival in Certain Advanced Lung Cancers

Posted 4 Jun 2015 by Drugs.com

THURSDAY, June 4, 2015 – Certain patients with lung cancer that's spread throughout the chest could live longer by undergoing surgery to remove diseased lung tissue, instead of receiving only chemotherapy and radiation, new research suggests. The study was based on a review of data on more than 9,000 patients with stage 3b non-small cell lung cancer – tumors that have spread to lymph nodes or other organs in the chest. The researchers found that those who underwent a combination of surgery, chemotherapy and radiation treatment lived an average of almost 10 months longer than those receiving chemo and radiation alone. Typically, surgery isn't offered to patients with such advanced cases of non-small cell lung cancer, physicians said, and some may also be too ill to undergo the procedure. However, "we think our study reignites a question that was initially asked in the 1980s and 1990s ... Read more

Related support groups: Surgery, Lung Cancer, Non-Small Cell Lung Cancer, Surgical Prophylaxis, Cardiothoracic Surgery

Exercise May Blunt a Woman's Risk of Lung and Breast Cancer: Studies

Posted 2 Jun 2015 by Drugs.com

TUESDAY, June 2, 2015 – Physical activity may reduce a woman's risk of lung or breast cancer, a pair of new studies suggest. Women seem less likely to either develop or die from lung cancer if they engage in physical activity, and the benefits increase the more a woman stays on the move, Stanford University researchers found. "We saw that as levels of physical activity increase, risk of lung cancer decreased," said lead author Ange Wang, a medical student at Stanford. Even active smokers enjoyed some protective benefit from lung cancer, when compared with couch potatoes who smoked, the researchers said. Meanwhile, a French study found that women may reduce by as much as one-third their risk of developing breast cancer by engaging in vigorous physical exercise. But that benefit did not extend to those who had ever taken hormone replacement therapy. Both studies were presented Monday at ... Read more

Related support groups: Smoking, Microgestin Fe 1/20, Loestrin 24 Fe, Breast Cancer, Estradiol, Premarin, Estrace, Lo Loestrin Fe, Ethinyl Estradiol, Junel Fe 1/20, Lung Cancer, Prempro, Vivelle, Vagifem, Estrace Vaginal Cream, Non-Small Cell Lung Cancer, Climara, Necon 1/35, Microgestin 1/20, Microgestin FE 1.5/30

Immune-Based Drug Shows Promise Against Advanced Lung Cancer

Posted 29 May 2015 by Drugs.com

FRIDAY, May 29, 2015 – A new drug appears to harness a person's immune system to fight the most common form of lung cancer, according to new clinical trial findings. The drug, nivolumab, reduced patients' risk of death from non-small cell lung cancer by 27 percent compared with patients who received docetaxel, a commonly used chemotherapy medication, researchers said. The study results are scheduled for presentation Saturday at the annual meeting of the American Society of Clinical Oncology, in Chicago. Nivolumab – marketed as Opdivo – primarily helps patients whose tumor cells carry a trait that allows their cancer to avoid detection by the immune system. As a result, overall median survival was 12.2 months in the nivolumab group compared to 9.4 months in the docetaxel group, the researchers reported. Also, only one in 10 patients experienced serious side effects with nivolumab, ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Taxotere, Docetaxel, Nivolumab, Docefrez, Opdivo

Can Statins Help Lower Lung Cancer Death Risk?

Posted 1 May 2015 by Drugs.com

FRIDAY, May 1, 2015 – Taking the cholesterol-lowering medications known as statins for a year before getting a diagnosis of lung cancer was associated with a 12 percent lower risk of dying from that cancer, new research suggests. The researchers from Northern Ireland also found indications that those who had a minimum of 12 statin prescriptions filled after being diagnosed with lung cancer saw their lung cancer death risk drop by as much as 19 percent. But, study lead author Chris Cardwell stressed that the degree of the association seen between statin use and a lower risk for lung cancer death was "relatively small." And while the study found an association between statin use and a lower risk of lung cancer death, it wasn't designed to prove a cause-and-effect relationship. Cardwell said there are any number of other differences between patients who take statins and patients who don't ... Read more

Related support groups: Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Lung Cancer, Non-Small Cell Lung Cancer, Vytorin, Rosuvastatin, Red Yeast Rice, Livalo, Pravachol, Simcor, Caduet, Lescol, Lescol XL, Mevacor, Pitavastatin

Drugs Show Promise for Some Advanced Lung Cancers

Posted 29 Apr 2015 by Drugs.com

WEDNESDAY, April 29, 2015 – Two experimental drugs may help patients whose lung cancer has become resistant to the latest available treatments, separate studies say. Both drugs showed benefits for patients with advanced lung cancer who develop a particular mutation that makes their tumors resistant to recently approved drugs called EGFR inhibitors. Currently, little can be done for those patients aside from chemotherapy. "And those chemotherapy agents don't do a great job," said Dr. Ramaswamy Govindan, an oncologist at Washington University School of Medicine in St. Louis. The two drugs are not "magic bullets," said Govindan, who wrote an editorial published with the studies in the April 30 issue of the New England Journal of Medicine. "But in the long struggle against lung cancer, this is a significant step," Govindan said. Among all people who develop non-small-cell lung cancer – by ... Read more

Related support groups: Lung Cancer, Tarceva, Non-Small Cell Lung Cancer, Erbitux, Iressa, Cetuximab, Gefitinib, Gilotrif, Erlotinib, Vectibix, Vandetanib, Tykerb, Afatinib, Panitumumab, Lapatinib, Caprelsa

Opdivo Approval Expanded to Include Lung Cancer

Posted 4 Mar 2015 by Drugs.com

WEDNESDAY, March 4, 2015 – U.S. Food and Drug Administration approval of Opdivo (nivolumab) has been expanded to include advanced non-small cell lung cancer (NSCLC), the agency said Wednesday in a news release. Lung cancer is the leading cause of cancer death in the United States, having been diagnosed more than 224,000 times and causing more than 159,000 deaths in 2014, the FDA said. NSCLC is the most common type, affecting seven of eight people with lung cancer. Opdivo inhibits a protein that prevents the immune system from attacking cancer cells, the agency said. The drug is sanctioned for people who have been treated with platinum-based chemotherapy. Opdivo was clinically compared to another anti-cancer drug, docetaxel, in a study involving more than 270 people with NSCLC. People who received Opdivo lived an average of 3.2 months longer than people given docetaxel, the FDA said. ... Read more

Related support groups: Non-Small Cell Lung Cancer, Opdivo, Nivolumab

FDA Expands Approved use of Opdivo (nivolumab) to Treat Lung Cancer

Posted 4 Mar 2015 by Drugs.com

March 4, 2015 – The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Lung cancer is the leading cause of cancer death in the United States, with an estimated 224,210 new diagnoses and 159,260 deaths in 2014. The most common type of lung cancer, NSCLC affects seven out of eight lung cancer patients, occurring when cancer forms in the cells of the lung. Opdivo works by inhibiting the cellular pathway known as PD-1 protein on cells that blocks the body’s immune system from attacking cancerous cells. Opdivo is intended for patients who have previously been treated with platinum-based chemotherapy. “The FDA worked proactively with the company to facilitate the early submission and review of this important ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Nivolumab, Opdivo

FDA Expands Approved use of Cyramza to Treat Aggressive Non-Small Cell Lung Cancer

Posted 12 Dec 2014 by Drugs.com

The U.S. Food and Drug Administration today expanded the approved use of Cyramza (ramucirumab) to treat patients with metastatic non-small cell lung cancer (NSCLC). The most common type of lung cancer, NSCLC occurs when cancer cells form in the tissues of the lung. The National Cancer Institute estimates that 224,210 Americans will be diagnosed and 159,260 will die from lung cancer in 2014. Cyramza works by blocking the blood supply that fuels tumor growth. The drug is intended for patients whose tumor has grown (progressed) during or following treatment with platinum-based chemotherapy, and it is to be used in combination with docetaxel, another type of chemotherapy. “Today’s approval is the third indication that Cyramza has received in 2014,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Th ... Read more

Related support groups: Non-Small Cell Lung Cancer, Cyramza, Ramucirumab

Cyramza Approval Expanded to Include Non-Small Lung Cancer

Posted 12 Dec 2014 by Drugs.com

FRIDAY, Dec. 12, 2014 – U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small cell lung cancer (NSCLC), the agency said Friday. NSCLC, the most common form of lung cancer, will be diagnosed in an estimated 224,000 Americans this year, and about 159,000 Americans will die from it, the FDA said, citing U.S. National Cancer Institute projections. Cyramza is designed to block the blood supply that feeds tumors. It's intended for people whose tumors have grown during or after treatment with other drugs. Cyramza was first approved in April to treat advanced cancers of the stomach or gastrointestinal tract, and approval was widened in November to include advanced gastric cancers. Clinical side effects have included a drop in germ-fighting white blood cells, inflammation of the mouth's lining, severe bleeding, ... Read more

Related support groups: Non-Small Cell Lung Cancer, Cyramza, Ramucirumab

FDA Approves Zykadia (ceritinib) for Metastatic Non-Small Cell Lung Cancer

Posted 29 Apr 2014 by Drugs.com

April 29, 2014 – The U.S. Food and Drug Administration today granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC). Zykadia is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that blocks proteins that promote the development of cancerous cells. It is intended for patients with metastatic ALK-positive NSCLC who were previously treated with crizotinib, the only other approved ALK tyrosine kinase inhibitor. Lung cancer is the leading cause of cancer-related deaths among men and women. According to the National Cancer Institute, an estimated 224,210 Americans will be diagnosed with lung cancer, and 159,260 will die from the disease this year. About 85 percent of lung cancers are NSCLC, making it the most common type of lung cancer. However, only 2-7 percent of patients with NSCLC ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer

Chemo Might Give Certain Lung Cancer Patients an Edge

Posted 8 Apr 2014 by Drugs.com

TUESDAY, April 8, 2014 – Cancer specialists have been unsure about how best to treat certain patients with an advanced form of lung cancer. Now, a new analysis of existing research finds that traditional chemotherapy outperforms newer, targeted treatments in delaying the time until the cancer worsens for these patients. However, chemo doesn't extend their survival, the review found. Patients with non-small cell lung cancer make up 85 percent to 90 percent of lung cancer patients. Some of them have a mutation in a gene that makes their tumors more responsive to medications known as epidermal growth factor receptor tyrosine kinase inhibitors. But most patients with non-small cell lung cancer do not have this mutation, and doctors have been unsure whether this larger group of patients should get chemo or the targeted medication. "In our opinion, conventional chemotherapy is a better ... Read more

Related support groups: Non-Small Cell Lung Cancer

Experimental Drug Shows Promise for Drug-Resistant Lung Cancer

Posted 26 Mar 2014 by Drugs.com

WEDNESDAY, March 26, 2014 – A new drug may help lung cancer patients when they become resistant to the first-line medication crizotinib, researchers find. Although crizotinib (brand name Xalkori) causes regression of a specific type of lung cancer, patients become resistant to it within about a year. But the new drug, ceritinib, seems effective against this type of lung cancer – called advanced ALK-positive non-small cell lung cancer – according to the results of early trials. "Ceritinib is even effective after the first-generation drug crizotinib has stopped working," said lead researcher Dr. Alice Shaw, an associate professor of medicine at Harvard Medical School in Boston. Preliminary results from this study led the U.S. Food and Drug Administration to give ceritinib a "breakthrough therapy" designation and led the drug's manufacturer to recommend accelerated approval, she said. ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Xalkori, Crizotinib

Page 1 2 3 4 5 6 7 Next

Ask a Question

Further Information

Related Condition Support Groups

Lung Cancer

Related Drug Support Groups

methotrexate, Tarceva, Avastin, Taxol, Taxotere, cisplatin, Xalkori, Gemzar, cyclophosphamide, view more... gemcitabine, paclitaxel, capecitabine, Iressa, Cyramza, docetaxel, Alimta, Gilotrif, gefitinib, erlotinib, cetuximab, Abraxane, bevacizumab, Platinol, vinorelbine, crizotinib, Navelbine, ramucirumab, amifostine, afatinib, pemetrexed, Trexall, Methotrexate LPF Sodium, Opdivo, Docefrez, Zykadia, Ethyol, ceritinib, porfimer, paclitaxel protein-bound, nivolumab, Onxol, Folex PFS, Photofrin, Platinol-AQ